OXFORD

RESEARCH ARTICLE

Preventing the Return of Fear Using Reconsolidation Update Mechanisms Depends on the Met-Allele of the Brain Derived Neurotrophic Factor Val66Met Polymorphism

Manish Kumar Asthana, PhD; Bettina Brunhuber; Andreas Mühlberger, PhD; Andreas Reif. MD; Simone Schneider, MD; Martin J. Herrmann, PhD

Social and Cognitive Neuroscience Laboratory, Mackenzie Presbyterian University, São Paulo, Brazil (Dr Asthana); Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Germany (Drs Brunhuber, Schneider, and Herrmann); Department of Psychology, University of Regensburg, Germany (Dr Mühlberger); Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University of Frankfurt, Germany (Dr Reif).

Correspondence: Martin J. Herrmann, PhD, Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Füchsleinstrasse 15, DE-97080 Würzburg, Germany (Herrmann_m@ukw.de).

Abstract

Background: Memory reconsolidation is the direct effect of memory reactivation followed by stabilization of newly synthesized proteins. It has been well proven that neural encoding of both newly and reactivated memories requires synaptic plasticity. Brain derived neurotrophic factor (BDNF) has been extensively investigated regarding its role in the formation of synaptic plasticity and in the alteration of fear memories. However, its role in fear reconsolidation is still unclear; hence, the current study has been designed to investigate the role of the *BDNF val66met* polymorphism (rs6265) in fear memory reconsolidation in humans.
Methods: An auditory fear-conditioning paradigm was conducted, which comprised of three stages (acquisition, reactivation, and spontaneous recovery). One day after fear acquisition, the experimental group underwent reactivation of fear memory followed by the extinction training (reminder group), whereas the control group (non-reminder group) underwent only extinction training. On day 3, both groups were subjected to spontaneous recovery of earlier learned fearful memories. The treat-elicited defensive response due to conditioned threat was measured by assessing the skin conductance response to the conditioned stimulus. All participants were genotyped for rs6265.
Results: The results indicate a diminishing effect of reminder on the persistence of fear memory only in the Met-allele carriers, suggesting a moderating effect of the *BDNF* polymorphism in fear memory reconsolidation.
Conclusions: Our findings suggest a new role for *BDNF* gene variation in fear memory reconsolidation in humans.

Keywords: BDNF, brain derived neurotrophic factor, fear conditioning, genetics memory, reconsolidation

Introduction

Overestimation of threatening situations is one major aspect for the development of pathological fear memories (Maren, 2011). Effective treatment of anxiety disorders depends on understanding how fear is memorized and regulated (Johansen et al., 2011). The most effective treatment used to address pathological fear is behavioral therapy based on exposure-based methods. In this form of therapy, threatening stimuli are presented repeatedly to the patients until the fear response is reduced or diminished (Myers and Davis, 2007). Much of our understanding emerges from the traditional Pavlovian fear-conditioning paradigm where a neutral stimulus (conditioned stimulus [CS]) is coupled with an unpleasant stimulus (unconditioned stimulus [UCS]). After a few CS-UCS couplings, the CS becomes effective in eliciting a fear-based conditioned response (CR) and thereby establishes a fear memory. The defensive response to the reinforced CS can be reduced or diminished through extinction training (i.e. repeated presentation of non-reinforced CS), thereby showing that the CS no longer predicts a threat (Myers and Davis, 2007; Johansen et al., 2011).

Nevertheless, a return of fear has been reported even after successful extinction training (Rescorla, 2004). Hence, much effort has been put into the development of effective treatment to prevent fear from returning. The efficacy of using pharmacological treatment to prevent pathological memories from returning has been well established, yet its effect in humans remains unpredictable and unverified (Rieder, 1994). Recent studies in both humans (Schiller et al., 2010; Agren et al., 2012a; Oyarzun et al., 2012) as well as animal models (Monfils et al., 2009) show that a single brief exposure of a non-reinforced CS used for memory reactivation just before extinction training can attenuate pathological memories. This attenuation could be due to the fact that memory becomes labile upon reactivation and undergoes reconsolidation. Nevertheless, some studies also failed to affect reconsolidation (Chan et al., 2010; Golkar et al., 2012; Kindt and Soeter, 2013; Wood et al., 2015). An important issue previously not addressed in detail is whether the failure to update old information (i.e. memory reconsolidation) might result from inter-individual differences (e.g. conferred by genetic variation as reported earlier; Agren et al., 2012b). The maintenance of reactivated fear memories (i.e. human fear reconsolidation) might be suppressed by certain allelic differences and enhanced by others. For example, individuals with the short-allele of the serotonin-transporter (5-*HTTLPR*) and *val/val* homozygotes of the functional *val158met* polymorphism of the *catechol O-methyltransferase* (*COMT*) exhibited the reacquisition of fear within the reconsolidation window (Agren et al., 2012b).

In addition to 5-*HTTLPR* and the *COMT* polymorphism, other polymorphisms have been shown to influence processes of learning and memory. For example, *Met*-allele carriers of brain-derived neurotrophic factor polymorhism (*BDNF val66met*) have been associated with alterations of hippocampal plasticity and weak episodic memory (Egan et al., 2003). In addition, the *met*-allele has been associated with the attenuation of hippocampal activation during encoding and retrieval of a declarative memory task (Hariri et al., 2003), which suggests a role in memory processes (Bekinschtein et al., 2007). Moreover, a recent animal study (Radiske et al., 2015) demonstrated a putative role of BDNF in the reconsolidation of extinction memory. It was shown that the direct infusion of BDNF into the hippocampus impaired reconsolidation of extinction memory both 6 hours or immediately after reactivation of learned fear in rats. This highlights an important role of BDNF in the maintenance of reactivated fear memories, and hence in the fear reconsolidation update mechanism as well.

Furthermore, the *BDNF val66met* polymorphism is closely associated with memory dysfunction (Monfils et al., 2007). The *met*-allele is associated with lower levels of activity-dependent secretion and distribution of BDNF protein in neurons (Egan et al., 2003) and with lower activity of BDNF secretion in general (Rybakowski, 2008), which leads to an impairment in learning and memory processes (Li et al., 2011). In accordance with the neurobiological effects of BDNF, the *BDNF val66met* polymorphism has been shown to modulate hippocampus-related memory processes (Chen et al., 2004). For example, animal studies have consistently affirmed the relevance of BDNF/neutrophic tyrosine kinase receptor B (TrkB) signalling in learning and memory processes (Minichiello, 2009; Li et al., 2011). In humans, *BDNF met*-allele carriers display differences in hippocampal morphology, which leads to selective memory dysfunction (Mukherjee et al., 2011).

Prior investigations (Egan et al., 2003; Cunha et al., 2010) have shown that increased expression and secretion of BDNF protein is strongly associated with learning and memory. This, it is possible that the *BDNF* polymorphism may modulate reactivated fear memories targeting reconsolidation mechanism. The involvement of BDNF in memory stabilization (Bekinschtein et al., 2007), resembles the reconsolidation mechanism, which acts to stabilizes a reactivated memory (Nadel and Land, 2000; Nadel et al., 2012). Such an interaction would suggest a failure to target reconsolidation and could be associated with inter-individual differences. Alternatively, the combined effect of reactivated memory and allelic differences might moderate the reconsolidation mechanism.

Therefore, we tested a large sample of healthy volunteers to investigate whether a functional *BDNF val66met* polymorphism affects the return of fear using reconsolidation update mechanisms (by applying reminder presentation followed by extinction training). We hypothesized that *BDNF met*-allele carriers would show less persistence of fear memory.

Materials and Method

Participants

One hundred and forty-three healthy participants of Caucasian descent were recruited via online advertisements to participate in the present study. The study was described briefly to the interested participants, with the information that the study was conducted on 3 consecutive days and included collection of a blood sample; 24 Euros were given as compensation. Participants were eligible for inclusion if they met the following criteria: (i) age 18–40 years; and (ii) German native speaker. Participants were excluded from the trial if they met the following criteria: (i) any neurological or psychiatric illnesses; (ii) pregnancy; or (iii) students with psychology as major. Information about these criteria was obtained through questionnaires (see below). Participants were randomly assigned into two groups: the reminder and non-reminder groups. After data analysis (see below), five participants were excluded due to artefacts (i.e. origin of response to stimuli before a baseline in more than eight numbers of trials resulting in less than three artefact-free trials for each condition) and 26 participants were excluded because they did not show a conditioned response (that means: conditioned stimuli CS+ > CS- during acquisition and also CS+ during

acquisition > CS+ during habituation). Four participants did not volunteer to participate in extinction training (24 hours later: day 2). Sixteen participants either did not donate blood or their blood samples could not be genotyped correctly, and one participant was dropped due to data corruption. The demographical data of the remaining 91 participants is shown in Table 1. According to recent literature (Hajcak et al., 2009; Lonsdorf et al., 2010; Torrents-Rodas et al., 2012), participants were placed into two groups: *met*-allele carriers (*met66met* and *val66met*) and *val*-allele homozygotes (*val66val*). Genotype groups did not differ with respect to sex and age (see Table 1). The study was in accordance with the declaration of Helsinki in its latest version from 2008 and has been approved by the local ethical board. All participants gave their written informed consent.

Psychometric Characterization

To characterize the participants of this study and to ensure that the different genotype groups did not differ with respect to relevant anxiety traits, the Anxiety Sensitivity Index (ASI 3; Taylor et al., 2007), the Fear Questionnaire (FQ; Marks and Mathews, 1979), the Positive And Negative Affect Scale (PANAS; Watson et al., 1988), the Penn State Worry Questionnaire (PSWQ; Meyer et al., 1990), the Spielberg State-Trait Anxiety Inventory (STAI-T; Spielberger and Gorsuch, 1983), the Allgemeine Depressions Skala (a screening instrument for depressive symptoms, in its short version; ADS-k; Hautzinger and Bailer, 1993), and the Behavioral Inhibition/Behavioral Approach System Scale (BIS/BAS scale) Carver and White, 1994) were completed by each participant. In Table 2, psychometric characteristics are given

for the two experimental groups (reminder vs non-reminder) and the two *BDNF* genotype groups (*met66met* and *val66met* vs *val66val*).

The main effect for BIS can be explained by higher values in *met*-allele carriers compared to *val66val* homozygotes. The main effect for PANAS1 (positive affect) can be explained by higher values in *val66val* homozygotes. The significant interaction effect of *BDNF* x group for PANAS2 (negative affect) can be explained by a lower negative affect in the no-reminder group for *met*-allele carriers compared to *val66val* homozygotes (t[48] = -2.2, *p* < 0.05). However, none of these main or interaction effects survive a strict Bonferroni correction with *p* < 0.004.

SCR Recording and Analyses

Skin conductance responses (SCRs) were recorded from the volar surfaces on medial phalanges of the participants' non-dominant palm (Dawson et al., 2000) as a means to measure the psychophysiological effects of fear learning. SCRs were recorded with the help of a V-Amp 16 (Brain Products GmbH), a 16-channel direct current amplifier system using the BrainVision Recorder Software (V-Amp Edition 1.10, Brain Products GmbH), at a sampling rate of 1000 Hz. All data was filtered with a 50 Hz notch filter during recording. SCRs were recorded using two Ag/AgCl electrodes (diameter = 13 mm) filled with non-hydrating gel.

SCRs data was filtered offline with a 1 Hz low pass filter and segmented into different phases (e.g. habituation, acquisition, extinction, and re-extinction) as well as single CS+ and CS- trials. Thereafter, each segment was baseline corrected 1000 ms prior to the onset of the stimuli and characterized by taking

Table 1. Descriptive Data of Final Sample by Reminder, Sex, and *BDNF* Genotype Subgroups

Experimental Group	Gender	Met66Met/ Val66Met	Val66Val	X^2	*p*-Value	d'
Reminder	Females	14.6 (6)	29.2 (12)	.01	.92	-.02
	Males	19.5 (8)	36.5 (15)			
Non-reminder	Females	24.0 (12)	24.0 (12)	.29	.59	.08
	Males	22.0 (11)	30.0 (15)			

Results are expressed as percentage with the number of subjects in brackets. n = 91

Table 2. Univariate Analysis of Variance Results

	Reminder		Non-Reminder		F-Values		
	Met66Met/ Val66Met	Val66Val	Met66Met/ Val66Met	Val66Val	R	B	R*B
FQ	1.47 (.82)	1.27 (.71)	1.21 (.71)	1.26 (.77)	0.72	.22	.64
PANAS1	2.27 (.28)	2.41 (.41)	2.17 (.38)	2.37 (.42)	.70	4.06*	.10
PANAS2	2.62 (.38)	2.51 (.39)	2.36 (.42)	2.60 (.36)	.90	.61	4.10*
PSWQ	2.30 (.41)	2.35 (.38)	2.11 (.47)	2.19 (.42)	3.65+	0.60	.03
STAI	1.00 (.47)	.99 (.50)	.72 (.59)	.90 (.48)	2.68	.62	.74
ADSk	.75 (.25)	.74 (.31)	.68 (.31)	.73 (.30)	0.08	3.45+	.00
BIS	2.25 (.27)	2.09 (.30)	2.27 (.34)	2.05 (.35)	.01	7.33**	.26
BAS drive	2.01 (.56)	2.05 (.47)	1.86 (.45)	1.86 (.58)	2.38	.02	.01
BAS fun seeking	1.98 (.57)	1.94 (.45)	1.84 (.45)	1.73 (.42)	2.87+	.67	.12
BAS reward resp	1.70 (.44)	1.60 (.40)	1.59 (.32)	1.42 (.31)	3.34+	2.94+	.19
ASI 3	1.00 (.47)	.99 (.49)	.73 (.59)	.91 (.48)	2.68	.62	.74

df = 89, displayed are the mean (with the standard deviation in brackets) for the four groups.
ADSk, Allgemeine Depressions Skala; ASI 3, Anxiety Sensitivity Index; B, main effects *BDNF* genotype group effects; BIS, Behavioral Inhibition System; BAS, Behavioral Approach System; BDNF, brain derived neurotrophic factor; FQ, Fear Questionnaire; PANAS, Positive and Negative Affect Scale; PANAS$_1$, positive affect; and PANAS$_2$, negative affect; PSWQ, Penn State Worry Questionnaire; R = main effects reminder group; R*B, interaction effects of R and B; STAI, Spielberger State-Trait Anxiety Inventory.
+*p* < 0.10, **p* <0.05, **p <0.01).

the maximum of the SCR deflection in the 1–4.5 second interval after stimulus onset, consistent with the previous study (Asthana et al., 2013). All SCRs scores were square root transformed to normalize distributions and were then range-corrected (Vansteenwegen et al., 2005; Schiller et al., 2010) by using the maximum (unconditioned) deflection (peak between 4.5 and 7.5 s during fear acquisition) elicited by the UCS as the maximum range for each individual.

Procedure

The present study was conducted on 3 consecutive days, 20 hours to 26 hours apart. The first session (day 1) consisted of a habituation and acquisition period, in which participants learned the association of conditioned (CS) and unconditioned stimuli (UCS). During these two phases, blue and yellow colored squares (presented at a 16 degree visual angle) were presented to the participants in a randomized order on a PC monitor for 4 s with an inter-stimulus interval of 10–12 s and counterbalanced as CS+ and CS- to each participant, so both squares were equally often selected as CS+ and CS-. Stimuli were presented in a pseudo-randomized order (i.e. not more than two consecutive trials of the same CS in a row were repeated) using Presentation Version 13.0 software (Neurobehavioral Systems, Inc.).

During the habituation phase, eight trials of each square (i.e. blue and yellow) were presented to reach a stable response to the stimuli. In the acquisition phase, 16 trials of squares of each color were presented. Along with one of the colored squares, a woman's scream (code number 276 adapted from the International Affective Digital Sounds for 2 s of 102 db loudness) was presented 2 s after CS+ onset, while the other square served as CS- (color was randomized between both conditions). Sixteen CS+ and CS- were presented, with an 80% reinforcement rate (i.e. 80% CS+ trials were paired with UCS).

During the second day (day 2), participants of the reminder group first underwent re-activation, which was followed by extinction training (16 CS+, 16 CS-). In the re-activation phase, a single presentation of the CS+ for 4 s without the UCS served as a reminder trial. The experimental group received the reminder trial 10 minutes before extinction training. In contrast, the reminder trial was never presented in the control group, but extinction training also started after a 10 minutes break. Extinction training consisted of repeated presentation of CS+ and CS- in absence of the UCS.

A day later (day 3), both groups (control and experimental group) underwent extinction training (16 CS+, 16 CS-) for a second time in order to trace the spontaneous recovery of previously learned fear memory contents. On all days, headphones and skin conductance electrodes were connected to all of the participants and the SCR were recorded from the start until the end (Asthana et al., 2013).

Genotyping

Participants were genotyped for the functional *BDNF val66met* polymorphism (rs6265) according to previously published protocols (Hunnerkopf et al., 2007). Genotyping was performed by standard polymerase chain reaction applying the following primers, forward (5′-AAA GAA GCA AAC ATC CGA GGA CAA G) and reverse (5′-ATT CCT CCA GCA GAA AGA GAA GAG G). The distribution of genotypes was in Hardy-Weinberg equilibrium (G/G: 54 [59.3%], G/A: 31 [34.1%], A/A: 6 [6.6 %], $\chi^2 = 0.29$, $p = 0.87$). The allele distribution did not differ between both experimental groups ($X^2 = 1.31$; n.s.; see Table 3).

Subjective Ratings

In the current study, individual fear learning was also assessed using ratings of subjective experience. As reported earlier, subjective experience is particularly sensitive to emotional valence and arousal. Moreover, in a fear conditioning paradigm, physiological recordings (e.g. skin conductance response) are sensitive to emotional arousal (Beckers et al., 2013). Subjective CS+ and CS- ratings were assessed at different experimental phases using self-assessment manikins (Bradley and Lang, 1994) for both valence and arousal. Subjects were asked to report whether the blue/yellow squares were perceived as pleasant or unpleasant and whether they induced arousal or calmness on a 9-point Likert scale. On the ratings of valence and arousal, 1 was labelled very unpleasant/calm, and 9 was labelled very pleasant/arousing, respectively. In addition, all participants were verbally questioned after each experimental phase about the perceived likelihood that the UCS occurred during the presentation of each CS+ (contingency awareness), although this response was not recorded.

Statistical Analysis

Preprocessing and statistical analysis were performed using Vision Analyzer 2.0 (Brain Products GmbH) and SPSS version 21.0 (IBM SPSS Statistics). Demographic data such as gender (male, female) and genotype (*met66met/met66val*, *val66val*) were compared between groups (reminder, no-reminder) by using a chi-square test (see Tables 1 and 3). Psychometric data (arousal, valence, ASI, FQ, PANAS, PSWQ, STAI-T, ADS-k, and BIS-BAS scores) were analyzed by using the univariate analysis of variance (see Table 2). The ratings for the arousal and valence are reported in the Supplementary Material (see Supplementary Table 1).

To evaluate fear conditioning, extinction, and spontaneous recovery, differential SCRs values (CS+ minus CS-) were calculated for each experimental phase (acquisition, extinction and re-extinction; Agren et al., 2012b). Furthermore, the two trials of both CS+ and CS- were averaged across the total number of trials (i.e. 16 trials in each). Each single trial block is comprised of two trials. Hence, in total we conducated four trial blocks during habituation and eight trial blocks each for CS+ and CS- during acquisition, extinction, and re-extinction. For the statistical analysis, the first four trial blocks (trials 1–8) were during acquisition, the last two trial blocks (trials 13–16) were during extinction, and the first trial block (trials 1–2) was taken into consideration and statistically evaluated using repeated measures analysis of variance (ANOVA) with phase mean as the within-subject factors and group (reminder, no-reminder) as the between-subject factor. To test the spontaneous recovery, the last two trial blocks of extinction and the first trial block of re-extinction were considered. Significant interaction effects were further elucidated by post-hoc t-tests at a significance level of $p < 0.05$ (two-tailed). Non-sphericity was considered by applying the Greenhouse-Geisser correction.

Results

Effect of Reactivation on Reconsolidation

The reminder group was given a single brief exposure of non-reinforced CS+ (without presentation of the UCS). The effect of

reactivation was evaluated by assessing whether there was an increase in Δ SCR (CS+ minus CS-) from the end of extinction (last two trials of day 2) to re-extinction (first two trials of day 3). This analysis revealed no effect of time (F [1, 89] = 0.18; p = 0.67), group (F[1,89] = 2.60; p = 0.11) or time x group (F [1, 89] = 0.30; p = 0.59), suggesting that reactivation of learned content did not affect memory reconsolidation.

Effect of Genotype on Reconsolidation

The effect of the reminder in relation to the *BDNF* genotype on fear reconsolidation (Figures 1B and 2A and B) was assessed using a three-way ANOVA with a 2 x 2 x 2 (group x genotype x time) design, for Δ SCRs (CS+ minus CS-) during extinction (again the last two trials of day 2) and re-extinction (first two trials of day 3). This showed a significant interaction effect of time x group x

Table 3. Percentage and Statistics of the Participants' Distribution Over *BDNF* Polymorphisms and Experimental Group

Experimental group	Met66Met	Val66Met	Val66Val	X^2	p-Value
Reminder	7.3 (3)	26.8 (11)	65.9 (27)	1.31	.25
Non-reminder	6.0 (3)	40.0 (20)	54.0 (27)		

Results are expressed as percentage with the number of subjects in brackets. BDNF, brain derived neurotrophic factor.

Figure 1. A brief single conditioned stimulus (CS) display (i.e. memory reactivation) followed by extinction training within a reconsolidation window prevents spontaneous recovery in *met*-allele carriers of the brain derived neurotrophic factor (*BDNF*) genotype in humans. (A) Schematic representation of experimental procedure and chronology. (B) Mean differential skin conductance response (SCR; CS+ minus CS-) during fear acquisition (early phase), extinction (last four trials), and test for spontaneous recovery (first two trials compared to last four trials of extinction) were observed in the 20–26 hours for each experimental group (reminder and no-reminder). The *met*-allele group is shown with black bars and the *non-met* group with grey bars. Each bar show the ΔSCRs (CS+ minus CS-) and the error bars reflect the standard error of the mean. Both genetic groups (*met*-allele and *non-met* allele) showed equivalent fear acquisition and extinction. Statistical test scores comparing different phases for both groups (reminder and no-reminder) by allelic differences (*met* and *non-met* allele) are as follows: fear acquisition (early phase (trials 1–8) versus fear extinction (trials 13–16) over both allele groups in the reminder group (t$_{met}$[13] = 3.16; p = 0.008; t$_{non-met}$[26] = 4.87; p = 0.000) and no-reminder group (t$_{met}$[22] = 6.78; p = 0.000; t$_{non-met}$[26] = 7.96; p = 0.000). Further, spontaneous recovery was considered by using the ΔSCRs during the extinction (trials 13–16) and re-extinction (trials 1–2). Our *t*-test revealed spontaneous recovery in *met*-carriers for the reminder group (t$_{met}$[13] = 3.34; p = 0.005) and no-reminder groups (t$_{met}$[22] = -2.27; p = 0.03). The *non-met* allele carriers showed non-significant spontaneous recovery in the reminder (t$_{non-met}$[26] = -0.66; p = 0.51) and no-reminder (t$_{non-met}$[26] = -0.27; p = 0.79) groups. *p < 0.05, **p < 0.01.

genotype (F [1, 87] = 11.89; $p < 0.001$). No significant main effect of time (F[1,87] = 0; $p = 0.99$), group (F[1,87] = 2.3; $p = 0.13$), genotype (F[1,87] = 1.66; $p = 0.20$), or further interaction effects were found (group x genotype, F[1,87] = 1.12, $p = 0.29$; group x time, F[1,87] = 1.56, $p = 0.22$; genotype x time, F[1,87] = 0.003, $p = 0.96$). Post hoc tests revealed a tendency for reduced amplitudes during re-extinction for the reminder group (t[13] = 1.83; $p < 0.10$) and increased amplitudes during re-extinction for the no-reminder group (t[22] = -2.88; $p < 0.01$), but only for *met* allele carriers. For *non-met* allele carriers, no significant differences between groups were found. Comparing the reminder group with the no-reminder group revealed significant higher amplitudes during re-extinction for *non-met* allele carriers (t[52] = 2.42; $p < 0.05$).

To investigate the interaction effect of time x group x genotype, we calculated the differences between re-extinction and extinction (thereby eliminating the factor time), with negative values indicating a decrease from day 2 to day 3 in SCR for the contrast (CS+ minus CS- condition; see Figure 2B).


Figure 2. (A) Differential (conditioned stimulus [CS+ minus CS-) skin conductance responses (SCRs) mean during extinction and re-extinction for both experimental groups and for the brain derived neurotrophic factor (*BDNF*) genotype. Error bars reflect standard error of the mean. (B) Differential (CS+ minus CS-) SCRs mean (re-extinction minus extinction) for both experimental groups and for *BDNF* genotype. Error bars reflect standard error of the mean. +$p < 0.10$, *$p < 0.05$, **$p < 0.01$.

A comparison of the reminder to the no-reminder groups revealed a significantly larger decrease in ΔSCRs (CS+ minus CS-) for the *met*-allele carriers from extinction to re-extinction (t[35] = -3.3; *p* < 0.003) in the reminder group. Additionally, we found that the *met*-allele carriers show a significantly larger decrease in the reminder group as compared to the *non-met* allele carriers (t[39] = -2.3; *p* < 0.05). Furthermore, within the no-reminder group we found a significantly larger decrease in the *non-met* carriers as compared to the *met*-allele carriers (t[35] = 2.6; *p* < 0.05).

Discussion

Blocking fear memory consolidation after reactivation moderates the return of fear (Monfils et al., 2009; Schiller et al., 2010), yet a significant number of studies have failed to target the reconsolidation mechanism and prevent fear from returning (Chan et al., 2010; Golkar et al., 2012; Kindt and Soeter, 2013; Wood et al., 2015). Schiller and colleagues (2010) developed the first drug-free paradigm that prevented fear memory from returning by using a reconsolidation mechanism in humans. Specifically, extinction training (i.e. repeated presentation of non-reinforced CSs) followed by memory reactivation has been shown to reduce the spontaneous recovery of fear the day after extinction training. It has been argued that the labile nature of memory after reactivation is necessary for memory maintenance or memory updating (Alberini, 2011). However, some studies failed to target the reconsolidation of memory in the human differential fear-conditioning paradigm. Therefore, our memory reactivation followed by extinction training is consistent with earlier investigations (Chan et al., 2010; Golkar et al., 2012; Kindt and Soeter, 2013) as it has been suggested that memory reactivation is not the sufficient condition for memory modification (Sevenster et al., 2012; Kindt and Soeter, 2013). The authors found evidence that a prediction error (i.e. the disparity between learned contingencies during fear acquisition and missing consequences during extinction training) is highly relevant for fear memory modification (Sevenster et al., 2013). Discrepant findings with regard to fear reconsolidation led to the proposed hypothesis that allelic differences can moderate the fear reconsolidation mechanism. BDNF has a role in the stabilization of memory in an associative learning paradigm (Bekinschtein et al., 2007), and thus may be a potential polymorphism for moderation of the fear reconsolidation mechanism. BDNF up- or down-regulation influences fear acquisition, extinction, and reacquisition. Rasmusson and co-workers (2002) showed in their study that the down-regulation of BDNF mRNA in the dentate gyrus of hippocampi in rats influences learning and memory. They also argued that reduction of BDNF mRNA in the dentate gyrus depends upon several factors, such as: (i) intensity, (ii) duration, and (iii) type of stress exposure. They explained that exposure to stressful cues, such as UCS or sensory cues associated with stressful situations, down-regulates the level of BDNF mRNA and reaches a normal level after 48 hours. Similarly, Bekinschtein and colleges (2007) demonstrated in their study that BDNF protein signalling is a necessary prerequisite for the stabilization of memory at an interval of 12 hours post-learning. This suggests (i) dynamic regulation of BDNF protein in memory formation and (ii) that delayed regulation of BDNF is important in the persistence of memory. Hence, we hypothesized that BDNF is necessary for memory stabilization via a process of memory reconsolidation. Consistent with this prediction, our results showed an attenuation of differential SCRs reflecting memory reconsolidation as modulated by *BDNF* polymorphism. Furthermore, only

met-carriers demonstrated reacquisition when presented with a reminder followed by extinction within the reconsolidation period, but not *BDNF val66val* allele homozygotes. These results suggest a hypostable pathological memory state in *met*-carriers, in accordance with previous studies (Chen et al., 2004) showing memory dysfunctions in *BDNF met*-allele carriers. The current results are aligned with the consistent findings that the *met*-allele of the *BDNF* polymorphism is responsible for impairment in learning and memory (Chen et al., 2006; Soliman et al., 2010; Papaleo et al., 2011). Moreover, neuroimaging evidence indicates that the *met*-allele carriers have reduced hippocampal and prefrontal cortex volumes compared to the *non-met* allele carriers (Pezawas et al., 2004).

Our results confirm those of a recent study (Radiske et al., 2015) showing that the intra-hippocampal infusion of BDNF antibodies immediately or 6 h after extinction memory reactivation impaired the reconsolidation of extinction memory in rats. This recent study demonstrated the significance of BDNF in the persistence of extinction memory after reactivation. Along the same line, we also observed a lower persistence of fear memory after reactivation of the *BDNF val66met* genotype in *met*-allele carriers.

One of the questions that arises from our study is how allelic differences influence human fear reconsolidation. To our knowledge, only one study in humans has addressed this issue. Agren and co-workers (2012b) reported the genetic modulation of fear memory persistence in humans selected for *5-HTTLPR* and *COMT* genotypes. Specifically, the *S*-carrier of *5-HTTLPR* and the *Val*-carrier of *COMT* displayed significantly higher SCRs for the reactivated-memory group outside the reconsolidation-window (i.e. 6 hours) compared to the group within the reconsolidation-window (i.e. 10 min). The moderating effect of the *BDNF* polymorphism that we report here shares similar findings as previous investigation (Agren et al., 2012b).

Our results are also interesting in light of genetic predictors in post-traumatic stress disorder (PTSD). There has been considerable speculation that the *BDNF* genotype plays a significant role in the pathogenesis of PTSD. This speculation arises from the fact that the variance of PTSD is naturally heritable (Domschke, 2012). Recent preliminary evidence has affirmed the association of the *BDNF* genotype with PTSD symptoms (Felmingham et al., 2013). The authors concluded that *met*-alleles showed behavioral resistance towards exposure therapy in PTSD compared to *val66val*. They also suggested the *met*-allele as a genetic predictor of exposure therapy in PTSD (Felmingham et al., 2013). The present finding suggests that the coupling of memory reconsolidation and exposure therapy in healthy subjects with the *met*-allele may be responsible for diminishing spontaneous recovery, further accounting for the discrepant research findings in memory reconsolidation (Chan et al., 2010; Golkar et al., 2012; Kindt and Soeter, 2013; Wood et al., 2015). It has been well esstablished that BDNF plays a critical role in the facilitation of neuronal differentiation and survival. Moreover, BDNF signalling is associated with abnormal fear memory and extinction (Autry and Monteggia, 2012). A common single-nucleotide in the BDNF polymorphism (rs6265), which results in a valine to methionine substitution (val66met), leads to impaired fear memory (Soliman et al., 2010). Specifically, Solimon et al. (2010) demonstrated the joint combination of heightened anxiety and impaired fear extinction in val66met compared to val-66val allele carriers.

The clinical relevance of memory modification through targeting the reconsolidation of pathological memory has recently gained much attention (Johansen et al., 2011; McKenzie and

Eichenbaum, 2011). A recent study tested for the first time whether reactivation of fear memory prior to exposure therapy reduces relapse in a randomized clinical sample of arachnophobes (Shiban et al., 2015). However, both the control and experimental group benefited significantly from treatment and a return of fear was not observed for either group. Therefore, more research on the mechanisms of memory reconsolidation and the effects of fear reactivation on memory is necessary in order to enhance the effects of exposure therapy in the context of persistent pathological fears. Based on the results of our study, we would suggest taking inter-individual differences into account, for example with respect to the *BDNF* genotype. Additionally, several other factors have been shown to play a significant role in memory modulation. Factors such as memory strength, age of memory, and specificity of the CS are known as boundary conditions of memory (Kwak et al., 2012). For example, strong memories are susceptible to disruption and do not undergo reconsolidation (Kindt and Soeter, 2013). Specifically, the rate of reinforcement level (i.e. CS-UCS associations) defines the strength of the memory, which directly affects memory reconsolidation after reactivation (Oyarzun et al., 2012).

We approached this study with the prior hypothesis that *BDNF* polymorphism partially prevents fear from returning by targeting a reconsolidation mechanism. However, the *BDNF val66met* polymorphism is unlikely to be the only genetic factor moderating the effects of reactivated fear memory on fear reconsolidation. It is likely that many other allelic differences are relevant in the persistence of fear memory in humans, as previously discussed. Although the current study demonstrated an effect of the *BDNF* polymorphism on fear memory reconsolidation and spontaneous recovery, some limitations of our finding must be taken into account. First, the small sample sizes of the groups may have affected the validity of the results. Second, we did not measure other threat-based physiological responses, such as the startle response, heart rate variability, and blood pressure. We also did not assess threat expectancies and contingency ratings for the CS-UCS association. The inclusion of other physiological and scaling data could have deepened our understanding of the threat expectancy and prediction error for different *BDNF* genotype groups. Finally, several undetected factors could also provide deeper insights into these measures, such as stress level and early undetected trauma. Despite these limitations, our study hints at the significant role of *BDNF* in fear memory reconsolidation after memory reactivation. In sum, our results show a moderation of a threat-based response after memory reactivation is significantly facilitated in *BDNF met*-carriers compared to *BDNF val66val* homozygotes.

Supplementary Material

For supplementary material accompanying this paper, visit http://dx.doi.org/10.1017/S00000000000000

Acknowledgments

Statement of Interest

References

Agren T, Engman J, Frick A, Bjorkstrand J, Larsson EM, Furmark T, Fredrikson M (2012a) Disruption of reconsolidation erases a fear memory trace in the human amygdala. Science 337:1550–1552.

Agren T, Furmark T, Eriksson E, Fredrikson M (2012b) Human fear reconsolidation and allelic differences in serotonergic and dopaminergic genes. Transl Psychiatry 2:e76.

Alberini CM (2011) The role of reconsolidation and the dynamic process of long-term memory formation and storage. Front Behav Neurosci 5:12.

Asthana M, Nueckel K, Muhlberger A, Neueder D, Polak T, Domschke K, Deckert J, Herrmann MJ (2013) Effects of transcranial direct current stimulation on consolidation of fear memory. Front Psychiatry 4:107.

Autry AE, Monteggia LM (2012) Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 64:238–258.

Beckers T, Krypotos AM, Boddez Y, Effting M, Kindt M (2013) What's wrong with fear conditioning? Biol Psychology 92:90–96.

Bekinschtein P, Cammarota M, Igaz LM, Bevilaqua LR, Izquierdo I, Medina JH (2007) Persistence of long-term memory storage requires a late protein synthesis- and BDNF- dependent phase in the hippocampus. Neuron 53:261–277.

Bradley MM, Lang PJ (1994) Measuring emotion: the self-assessment manikin and the semantic differential. J Behav Ther Exp Psychiatry 25:49–59.

Carver CS, White TL (1994) Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. J Pers Soc Psychol 67:319–333.

Chan WY, Leung HT, Westbrook RF, McNally GP (2010) Effects of recent exposure to a conditioned stimulus on extinction of Pavlovian fear conditioning. Learn Mem 17:512–521.

Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004) Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24:4401–4411.

Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, Herrera DG, Toth M, Yang C, McEwen BS, Hempstead BL, Lee FS (2006) Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314:140–143.

Cunha C, Brambilla R, Thomas KL (2010) A simple role for BDNF in learning and memory? Front Mol Neurosci 3:1.

Dawson M, Schell A, Filion D (2000) In: Handbook of Psychophysiology (J.T. Cacioppo, L.G. Tassinary, & G.L. Bernston, eds), pp. 200–223. Cambridge: Cambridge University Press.

Domschke K (2012) Patho-genetics of posttraumatic stress disorder. Psychiatr Danub 24:267–273.

Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112:257–269.

Felmingham KL, Dobson-Stone C, Schofield PR, Quirk GJ, Bryant RA (2013) The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol Psychiatry 73:1059–1063.

Golkar A, Bellander M, Olsson A, Ohman A (2012) Are fear memories erasable?-reconsolidation of learned fear with fear-relevant and fear-irrelevant stimuli. Front Behav Neurosci 6:80.

Hajcak G, Castille C, Olvet DM, Dunning JP, Roohi J, Hatchwell E (2009) Genetic variation in brain-derived neurotrophic factor and human fear conditioning. Genes Brain Behav 8:80–85.

Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR (2003) Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 23:6690–6694.

Hunnerkopf R, Strobel A, Gutknecht L, Brocke B, Lesch KP (2007) Interaction between BDNF Val66Met and dopamine transporter gene variation influences anxiety-related traits. Neuropsychopharmacology 32:2552–2560.

Johansen JP, Cain CK, Ostroff LE, LeDoux JE (2011) Molecular mechanisms of fear learning and memory. Cell 147:509–524.

Kindt M, Soeter M (2013) Reconsolidation in a human fear conditioning study: a test of extinction as updating mechanism. Biol Psychology 92:43–50.

Kwak C, Choi JH, Bakes JT, Lee K, Kaang BK (2012) Effect of intensity of unconditional stimulus on reconsolidation of contextual fear memory. Korean J Physiol Pharmacol 16:293–296.

Li Y, Tang K, Zhang H, Zhang Y, Zhou W, Chen X (2011) Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp. Mol Med Rep 4:739–746.

Lonsdorf TB, Weike AI, Golkar A, Schalling M, Hamm AO, Ohman A (2010) Amygdala-dependent fear conditioning in humans is modulated by the BDNFval66met polymorphism. Behav Neurosci 124:9–15.

Hautzinger M, Bailer M (1993) Allgemeine depressions skala. Manual. Göttingen, Germany: Beltz Test GmbH.

Maren S (2011) Seeking a spotless mind: extinction, deconsolidation, and erasure of fear memory. Neuron 70:830–845.

Marks IM, Mathews AM (1979) Brief standard self-rating for phobic patients. Behav Res Ther 17:263–267.

McKenzie S, Eichenbaum H (2011) Consolidation and reconsolidation: two lives of memories? Neuron 71:224–233.

Meyer TJ, Miller ML, Metzger RL, Borkovec TD (1990) Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 28:487–495.

Minichiello L (2009) TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10:850–860.

Monfils MH, Cowansage KK, LeDoux JE (2007) Brain-derived neurotrophic factor: linking fear learning to memory consolidation. Mol Pharmacol 72:235–237.

Monfils MH, Cowansage KK, Klann E, LeDoux JE (2009) Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories. Science 324:951–955.

Mukherjee P, Whalley HC, McKirdy JW, McIntosh AM, Johnstone EC, Lawrie SM, Hall J (2011) Effects of the BDNF Val66Met polymorphism on neural responses to facial emotion. Psychiatry Res 191:182–188.

Myers KM, Davis M (2007) Mechanisms of fear extinction. Mol Psychiatry 12:120–150.

Nadel L, Land C (2000) Commentary reconsolidation: memory traces revisited. Nat Rev Neurosci 1:209–212.

Nadel L, Hupbach A, Gomez R, Newman-Smith K (2012) Memory formation, consolidation and transformation. Neurosci Biobehav Rev 36:1640–1645.

Oyarzun JP, Lopez-Barroso D, Fuentemilla L, Cucurell D, Pedraza C, Rodriguez-Fornells A, de Diego-Balaguer R (2012) Updating fearful memories with extinction training during reconsolidation: a human study using auditory aversive stimuli. PLOS ONE 7:e38849.

Papaleo F, Silverman JL, Aney J, Tian Q, Barkan CL, Chadman KK, Crawley JN (2011) Working memory deficits, increased anxiety-like traits, and seizure susceptibility in BDNF overexpressing mice. Learn Mem 18:534–544.

Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR (2004) The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24:10099–10102.

Radiske A, Rossato JI, Kohler CA, Gonzalez MC, Medina JH, Cammarota M (2015) Requirement for BDNF in the reconsolidation of fear extinction. J Neurosci 35:6570–6574.

Rasmusson AM, Shi L, Duman R (2002) Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology 27:133–142.

Rescorla RA (2004) Spontaneous recovery. Learn Mem 11:501–509.

Rieder MJ (1994) Mechanisms of unpredictable adverse drug reactions. Drug Safety 11:196–212.

Rybakowski JK (2008) BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 9:1589–1593.

Schiller D, Monfils MH, Raio CM, Johnson DC, Ledoux JE, Phelps EA (2010) Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 463:49–53.

Sevenster D, Beckers T, Kindt M (2012) Retrieval per se is not sufficient to trigger reconsolidation of human fear memory. Neurobiol Learn Mem 97:338–345.

Sevenster D, Beckers T, Kindt M (2013) Prediction error governs pharmacologically induced amnesia for learned fear. Science 339:830–833.

Shiban Y, Brutting J, Pauli P, Muhlberger A (2015) Fear reactivation prior to exposure therapy: does it facilitate the effects of VR exposure in a randomized clinical sample? J Behav Ther Exp Psychiatry 46:133–140.

Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS, Jing D, Tottenham N, Amso D, Somerville LH, Voss HU, Glover G, Ballon DJ, Liston C, Teslovich T, Van Kempen T, Lee FS, Casey BJ (2010) A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327:863–866.

Spielberger CD, Gorsuch RL (1983) Manual for the state-trait anxiety inventory (form Y; self-evaluation questionnaire). Palo Alto, CA: Consulting Psychologists Press.

Taylor S, Zvolensky MJ, Cox BJ, Deacon B, Heimberg RG, Ledley DR, Abramowitz JS, Holaway RM, Sandin B, Stewart SH, Coles M, Eng W, Daly ES, Arrindell WA, Bouvard M, Cardenas SJ (2007) Robust dimensions of anxiety sensitivity: development and initial validation of the Anxiety Sensitivity Index-3. Psychol Assessment 19:176–188.

Torrents-Rodas D, Fullana MA, Arias B, Bonillo A, Caseras X, Andion O, Mitjans M, Fananas L, Torrubia R (2012) Acquisition and generalization of fear conditioning are not modulated by the BDNF-val-66met polymorphism in humans. Psychophysiology 49:713–719.

Vansteenwegen D, Hermans D, Vervliet B, Francken G, Beckers T, Baeyens F, Eelen P (2005) Return of fear in a human differential conditioning paradigm caused by a return to the original acquistion context. Behav Res Ther 43:323–336.

Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063–1070.

Wood NE, Rosasco ML, Suris AM, Spring JD, Marin MF, Lasko NB, Goetz JM, Fischer AM, Orr SP, Pitman RK (2015) Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies. Psychiatry Res 225:31–39.